

**September 1, 2009**

**AlphaVax Progresses H1N1 Influenza Vaccine.** AlphaVax announced today further progress in the development of an influenza H1N1 vaccine, which capitalizes on the strengths of its proprietary vector platform, namely (i) speed to manufacture, (ii) use of cell culture rather than eggs, and (iii) the generation of robust immune responses that provides both antibody and killer T cell responses.

AlphaVax has now completed, within 11 weeks of receipt of the H1 hemagglutinin (HA) gene, the initial GMP-compliant manufacture of an H1N1 vaccine. Yields are some of the highest experienced by AlphaVax in over 50 lots that have been manufactured at its Lenoir facility, including lots for a seasonal influenza vaccine previously tested clinically [\[1\]](#). This contrasts with the reported experience with egg-based production of H1N1 vaccines, where yields are lower than those expected for seasonal influenza vaccine production. The manufacturing process can be economically scaled to meet demand, since the process is based on the use of disposable equipment.

AlphaVax's H1N1 vaccine has been tested in both primates and swine, where 100% of animals developed hemagglutination inhibition (HI) antibody levels considered to be sero-protective following a two-dose immunization protocol (similar to the schedules currently being tested in human trials of the egg-based H1N1 vaccines).